Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes

Diabetic Medicine

Volumn 33, Issue 12, 2016, Pages 1732-1736

  Wang, Y ^a   Xu, L ^b   Yuan, L ^a   Li, D ^a   Zhang, Y ^a   Zheng, R ^a   Liu, C ^a   Feng, X ^a   Li, Q ^a   Ma, J ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Kunshan Rehabilitation Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; C PEPTIDE; DAPAGLIFLOZIN; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PANCREAS ISLET CELL ANTIBODY; PLACEBO; SODIUM; TRIACYLGLYCEROL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; GLUCOSE BLOOD LEVEL; METABOLISM; PANCREAS ISLET BETA CELL; PHYSIOLOGY; SECRETION (PROCESS);

ATRIAL NATRIURETIC FACTOR; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORT PROTEINS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84994910800     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13107     Document Type: Article

References (15)

1. Shi Y, Hu FB. The global implications of diabetes and cancer. Lancet 2014; 383: 1947–1948.
2. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. 2013. Available at http://www.idf.org/diabetesatlas/update-2014 Last accessed 17 June 2014.
3. Misra M. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharmacy Pharmacol 2013; 65: 317–327.
4. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2014; 104: 297–322.
5. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014; 16: 457–466.
6. Gruden G, Landi A, Bruno G. Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research. Diabetes Care 2014; 37: 2899–2908.
7. Majowicz MP, Gonzalez Bosc LV, Albertoni Borghese MF, Delgado MF, Ortiz MC, Sterin Speziale N et al. Atrial natriuretic peptide and endothelin-3 target renal sodium-glucose cotransporter. Peptides 2003; 24: 1971–1976.
8. Gonzalez Bosc LV, Elustondo PA, Ortiz MC, Vidal NA. Effect of atrial natriuretic peptide on sodium-glucose cotransport in the rat small intestine. Peptides 1997; 18: 1491–1495.
9. Schlueter N, de Sterke A, Willmes DM, Spranger J, Jordan J, Birkenfeld AL. Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. Pharmacol Ther 2014; 144: 12–27.
10. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M et al. Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 2009; 58: 2880–2892.
11. Wang TJ. The natriuretic peptides and fat metabolism. N Engl J Med 2012; 367: 377–378.
12. Martinez Seeber A, Vidal NA, Carchio SM, Karara AL. Inhibition of water-sodium intestinal absorption by an atrial extract. Can J Physiol Pharmacol 1986; 64: 244–247.
13. You H, Laychock SG. Atrial natriuretic peptide promotes pancreatic islet beta-cell growth and Akt/Foxo1a/cyclin D2 signaling. Endocrinology 2009; 150: 5455–5465.
14. Kroon MH, van den Hurk K, Alssema M, Kamp O, Stehouwer CD, Henry RM et al. Prospective associations of B-type natriuretic peptide with markers of left ventricular function in individuals with and without type 2 diabetes: an 8-year follow-up of the Hoorn Study. Diabetes Care 2012; 35: 2510–2514.
15. Cosson E, Nguyen MT, Pham I, Pontet M, Nitenberg A, Valensi P. N-terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. Diabet Med 2009; 26: 872–879.